Newleos Announces Dosing of First Participant in Phase 1b Study of NTX-2001 for Alcohol Use Disorder April 29, 2026
Newleos Announces Dosing of First Participant inU.K. Phase 1b Study of NTX-1955 in Generalized Anxiety Disorder April 1, 2026
Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder January 6, 2026
Newleos Therapeutics Appoints Timothy Noyes as President and Chief Executive Officer October 22, 2025
